logo.png
Precede Biosciences Presents New Data at AACR LBx 2024 Demonstrating an Accurate Readout of Tumor PSMA Expression and Stratification of Response to Lutetium-PSMA in Men with mCRPC from a Simple Blood Test
15 nov. 2024 21h15 HE | Precede Biosciences, Inc.
Results show the potential of a real-time, non-invasive blood test to quantify tumor drug target expression and to stratify therapeutic response to Lutetium-PSMABeyond Lutetium-PSMA, these results are...
2025 MDA Clinical & Scientific Conference
Agenda Announced for 2025 MDA Clinical & Scientific Conference Featuring Leading Speakers Dedicated to Groundbreaking Research and Clinical Achievements in Neuromuscular Disease
14 nov. 2024 09h00 HE | Muscular Dystrophy Association
New York, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association today announced the agenda including tracks and Chairs for the 2025 MDA Clinical & Scientific Conference being held...
Transparency Market Research
ELISA Analyzers Market Size Forecast to Hit USD 960.7 Million by 2031, Growing at a CAGR of 5.9%| Says Transparency Market Research, Inc.
12 nov. 2024 10h31 HE | Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research, Inc. , Nov. 12, 2024 (GLOBE NEWSWIRE) -- The ELISA analyzers market was valued at US$ 574.7 million in 2022. Between 2023 and 2031,...
Logo_AdipoPharma_V1.png
French Biotech Company AdipoPharma Secures Funding to Initiate Clinical Trials for its first-in-class compound for Insulin Resistance
11 nov. 2024 12h43 HE | AdipoPharma
STRASBOURG, France, Nov. 11, 2024 (GLOBE NEWSWIRE) -- AdipoPharma, a biotech company headquartered in France with offices in the US and Belgium developing a novel and promising Type 2 diabetes drug,...
Externally-Led Patient Focused Drug Development (EL-PFDD) Meeting on Sarcoidosis patients and caregivers
Nearly 350 Patients Participate in the Foundation for Sarcoidosis Research Externally Led Patient-Focused Drug Development Meeting with the FDA
31 oct. 2024 15h28 HE | Foundation for Sarcoidosis Research
Foundation for Sarcoidosis Research (FSR) hosts Externally Led Patient-Focused Drug Development (EL-PFDD) meeting for Sarcoidosis
Tevogen Logo Notified.png
Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs
31 oct. 2024 10h54 HE | Tevogen Bio Inc
Current timeline for drug development is 10-12 years and costs approximately $1-3 billion. Tevogen’s approach has the potential to shorten timelines and substantially reduce costs. Tevogen’s AI...
Image press release Bioanalytical Expansion
Ardena Expands Bioanalytical Services in Europe
29 oct. 2024 07h24 HE | Ardena Holding NV.
Ardena expands bioanalytical services in the Netherlands with a new lab in Oss and enhanced capabilities in Assen to meet rising client demand.
Multiomics Market
Multiomics Markets Report 2024-2029: Major Players, Products, Platforms, Applications, Market Dynamics, and Geographic Opportunities
29 oct. 2024 06h48 HE | Research and Markets
Dublin, Oct. 29, 2024 (GLOBE NEWSWIRE) -- The "Multiomics Market" report has been added to ResearchAndMarkets.com's offering. The global market for multiomics is expected to grow from $2.7...
22157.jpg
Optical Tweezers (Mechanobiology) Market Report 2024-2034 - Integration with Other Technologies like Raman Spectroscopy and Fluorescence Microscopy Presents Opportunities
28 oct. 2024 05h20 HE | Research and Markets
Dublin, Oct. 28, 2024 (GLOBE NEWSWIRE) -- The "Optical Tweezers (Mechanobiology) Market Report 2024-2034" has been added to ResearchAndMarkets.com's offering.World revenue for the Optical Tweezers...
Tevogen Logo Notified.png
Tevogen Bio’s Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating drug Development
23 oct. 2024 08h35 HE | Tevogen Bio Inc
WARREN, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...